Folgen
solange peters
solange peters
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei chuv.ch
Titel
Zitiert von
Zitiert von
Jahr
Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
Nature 511 (7511), 543, 2014
37842014
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
24652017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ...
Annals of Oncology 29, iv192-iv237, 2018
2345*2018
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ...
New England Journal of Medicine 377 (9), 829-838, 2017
22692017
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
21952019
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of oncology 28, iv119-iv142, 2017
21892017
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ...
Annals of Oncology 30 (1), 44-56, 2019
19802019
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18052020
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ...
Annals of oncology 28, iv1-iv21, 2017
16952017
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ...
Nature reviews Clinical oncology 16 (9), 563-580, 2019
14892019
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ...
Annals of Oncology 27, v1-v27, 2016
9822016
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Reck, S Popat, N Reinmuth, D De Ruysscher, KM Kerr, S Peters
Annals of oncology 25, iii27-iii39, 2014
7872014
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ...
The Lancet 397 (10272), 375-386, 2021
7702021
Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti, MS Ahluwalia, L Nayak, ...
Nature Reviews Disease Primers 5 (1), 5, 2019
7652019
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ...
Journal of clinical oncology 31 (16), 1997-2003, 2013
7292013
Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of Oncology 29, iv264-iv266, 2018
700*2018
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Früh, D De Ruysscher, S Popat, L Crinò, S Peters, E Felip
Annals of oncology 24, vi99-vi105, 2013
6922013
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
6412020
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ...
Annals of oncology 24, vi89-vi98, 2013
6362013
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Peters, AA Adjei, C Gridelli, M Reck, K Kerr, E Felip
Annals of oncology 23, vii56-vii64, 2012
5732012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20